“Bolar Amendment” Provides Broad Protection For Drug Research, Supreme Court Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Waxman/Hatch safe harbor from patent infringement claims encompasses preclinical research on compounds that are not ultimately the subject of an FDA submission, the Supreme Court unanimously rules in the Merck v. Integra case.